Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX01 in Pain Due to Erythromelalgia
NCT05917912Phase 2Completed
- Sponsor
- AlgoTherapeutix
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Gene Editing, Gene Silencing, Modified DNA Oligonucleotides
- Countries
- 2
01
Overview
A Phase 2 trial of ATX-01 in erythromelalgia, sponsored by AlgoTherapeutix. Started Jun 2023; status: completed.
02
Drugs
ATX-01
03
Conditions
erythromelalgia
Beyond the preview
Go deeper on NCT05917912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917912.